About HitGen
HitGen is a company based in Lanzhou (China) founded in 2012. It operates as a Professional Services and SaaS (Software-as-a-Service). HitGen has raised $39.11 million across 2 funding rounds from investors including Gates Foundation, CDH and Shiyu Capital. The company has 483 employees as of December 31, 2024. HitGen has completed 1 acquisition, including Vernalis. HitGen offers products and services including DNA Encoded Library (DEL), Fragment-Based Drug Discovery (FBDD/SBDD), Oligonucleotide-Based Therapeutics (OBT), and Targeted Protein Degradation (TPD). HitGen operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Omniome, among others.
- Headquarter Lanzhou, China
- Employees 483 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hitgen Inc. Class A
-
Annual Revenue
$58.19 M (USD)15.58as on Dec 31, 2024
-
Net Profit
$7.04 M (USD)26.13as on Dec 31, 2024
-
EBITDA
$15.97 M (USD)94.03as on Dec 31, 2024
-
Total Equity Funding
$39.11 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
Gates Foundation
& 2 more
-
Employee Count
483
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of HitGen
HitGen is a publicly listed company on the SSE with ticker symbol 688222 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of HitGen
HitGen offers a comprehensive portfolio of products and services, including DNA Encoded Library (DEL), Fragment-Based Drug Discovery (FBDD/SBDD), Oligonucleotide-Based Therapeutics (OBT), and Targeted Protein Degradation (TPD).
Technology used for designing and screening compound libraries.
Methods applied for structure-based drug design optimization.
Platform developed for nucleic acid drug discovery.
Technology utilized for protein degradation drug development.
People of HitGen
Unlock access to complete
Funding Insights of HitGen
HitGen has successfully raised a total of $39.11M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HitGen
HitGen has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, CDH and Shiyu Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and private debt firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Shiyu Capital is engaged in equity investment and asset allocation.
|
Locked | Locked | Locked | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked |
Investor details for HitGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HitGen
HitGen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Vernalis.
Investment portfolio details for HitGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Vernalis is engaged in structure-based drug discovery collaborations.
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for HitGen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - HitGen
Detailed financials for HitGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hitgen Comparisons
Peer comparison for HitGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HitGen
HitGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Omniome, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
Detailed competitors of HitGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hitgen
Complete news archive for HitGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HitGen
HitGen was founded in 2012 and raised its 1st funding round 6 years after it was founded.
HitGen is headquartered in Lanzhou, China. It is registered at Lanzhou, Gansu, China.
Jin Li is the current CEO of HitGen.
HitGen is a funded company, having raised a total of $39.11M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at HitGen is 483.
Annual revenue of HitGen is $58.19M as on Dec 31, 2024.
HitGen Inc. is involved in drug discovery research, focusing on the development of novel medicines and agrochemicals. The company is headquartered in Chengdu, China, with operations in the UK and USA. Advanced technology platforms such as DNA-encoded library (DEL), fragment-based drug discovery (FBDDSBDD), oligonucleotide-based therapeutics (OBT), and targeted protein degradation (TPD) are utilized. Collaboration with numerous biopharmaceutical organizations worldwide is maintained, supporting projects from early discovery to clinical trials. A DELAIAutomated DMTA platform is being developed to enhance preclinical candidate optimization. Diverse sectors including healthcare and agriculture are served through flexible business models.
HitGen's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
HitGen offers DNA Encoded Library (DEL), Fragment-Based Drug Discovery (FBDD/SBDD), Oligonucleotide-Based Therapeutics (OBT), and Targeted Protein Degradation (TPD).
Yes, HitGen is publicly traded on SSE under the ticker symbol 688222.
HitGen has made 1 acquisition, including Vernalis.
HitGen has 3 investors. Key investors include Gates Foundation, CDH, and Shiyu Capital.
The ticker symbol of HitGen is 688222 on SSE.